OpenAI Restricts Astra AI Over Cyberattack Risks 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
ANAHEIM, CA, March 01, 2018 -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it will host a conference call on Thursday, March 8th at 2:00 p.m. Eastern Time to discuss the Company's corporate progress and recent developments.
The call will be available on the Company’s website at www.BioCorRx.com, or by calling 877-407-8031 for U.S. callers or +1 201-689-8031 for international callers.
A webcast will also be archived on the Company’s website and a teleconference replay of the conference call will be available approximately one hour following the call, through midnight March 22, 2018, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 26575.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. [email protected] 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 [email protected]
